Erika Rijavec
- Oncology top 2%
- Pulmonary and Respiratory Medicine top 5%
- Molecular Biology
- Cancer Research top 5%
- Immunology top 10%
- Co-authors
- Francesco GrossiCarlo GenovaAlice IndiniSimona CocoMaria Giovanna Dal BelloFederica BielloAngela AlamaGiovanni Rossi
- Topics
- Lung Cancer Treatments and Mutations (46 papers)Cancer Immunotherapy and Biomarkers (31 papers)Lung Cancer Research Studies (18 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaCancer
- Partner nations
- ItalyUnited StatesUnited Kingdom
In The Last Decade
Erika Rijavec
92 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 98
- Oncology 1.1k
- Pulmonary and Respiratory Medicine 707
- Molecular Biology 489
- Cancer Research 420
- Immunology 253
Countries citing papers authored by Erika Rijavec
This map shows the geographic impact of Erika Rijavec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erika Rijavec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erika Rijavec more than expected).
Fields of papers citing papers by Erika Rijavec
This network shows the impact of papers produced by Erika Rijavec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erika Rijavec. The network helps show where Erika Rijavec may publish in the future.
Co-authorship network of co-authors of Erika Rijavec
This figure shows the co-authorship network connecting the top 25 collaborators of Erika Rijavec. A scholar is included among the top collaborators of Erika Rijavec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erika Rijavec. Erika Rijavec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib | 7 |
| 2 | 32 | |
| 3 | 20 | |
| 4 | 8 | |
| 5 | 1 | |
| 6 | 7 | |
| 7 | 21 | |
| 8 | 4 | |
| 9 | 2 | |
| 10 | 45 | |
| 11 | 28 | |
| 12 | 22 | |
| 13 | 23 | |
| 14 | 3 | |
| 15 | 11 | |
| 16 | 17 | |
| 17 | 27 | |
| 18 | 37 | |
| 19 | 33 | |
| 20 | 20 |
About Erika Rijavec
Erika Rijavec is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 93 papers that have together received 1.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (46 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Lung Cancer Research Studies (18 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (420 citations) and Pulmonary and Respiratory Medicine (707 citations). Erika Rijavec has collaborated with scholars based in Italy, United States and United Kingdom. Frequent co-authors include Francesco Grossi, Carlo Genova, Alice Indini, Simona Coco, Maria Giovanna Dal Bello, Federica Biello, Angela Alama, Giovanni Rossi, Giulia Barletta and Michele Ghidini. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.